DocDePanda187123
fitasfuk50's Operating System
- Joined
- Sep 26, 2013
- Messages
- 8,074
- Reaction score
- 5,826
- Points
- 283
This was posted by Dr. Scally elsewhere. Interesting to say the least and does help the argument that test and E2 is the culprit behind increased prolactin and not tren or deca.
Increased Prevalence of Hypoprolactinemia in Men Taking testosterone Supplementation Therapy
Introduction and Objectives - The purpose of this study is to determine whether or not there was a difference in the prevalence of hypoprolactinemia in patients taking testosterone supplementation therapy (TST) when compared to men not on TST.
Methods - We performed a retrospective analysis of men who presented to an academic urology clinic and had available medication usage and prolactin levels. Patients taking cabergoline were excluded from the study.
We compared the prevalence of hypoprolactinemia at different cut-points (<1, <3, and <6 ng/ml) using a Pearson Chi-Square test with a significance of p<0.05.
Results - 4,551 men were included for analysis with a mean age of 45.5 years (Range: 15-96, Std.Dev: 13.197). 49% (n=2242) of men were on TST and 51% (n=2.309) were not.
There was a greater prevalence of hypoprolactinemia in men on TST than in men not on TST for prolactin cut-points of <6 ng/mL (40.4% vs. 29.6%, p=0.001) and <3 ng/mL (3.4% vs. 1.8%, p=0.001). There was no statistical difference in the prevalence of profound hypoprolactinemia (<1ng/mL) between men on TST and not on TST (0.4% vs. 0.1%, p=0.074).
Conclusions - Prolactin appears to be involved in the central control of sexual function through modulation of dopaminergic and serotoninergic systems.
Hypoprolactinemia has also been associated with metabolic syndrome, arteriogenic erectile dysfunction, premature ejaculation, and anxiety.
Our study demonstrated that there is a greater prevalence of hypoprolactinemia in men taking testosterone supplementation therapy when compared to men not taking exogenous testosterone.
Given this finding, patients on TST may need to be monitored for possible development of signs and symptoms related to low prolactin levels.
Increased Prevalence of Hypoprolactinemia in Men Taking testosterone Supplementation Therapy
Introduction and Objectives - The purpose of this study is to determine whether or not there was a difference in the prevalence of hypoprolactinemia in patients taking testosterone supplementation therapy (TST) when compared to men not on TST.
Methods - We performed a retrospective analysis of men who presented to an academic urology clinic and had available medication usage and prolactin levels. Patients taking cabergoline were excluded from the study.
We compared the prevalence of hypoprolactinemia at different cut-points (<1, <3, and <6 ng/ml) using a Pearson Chi-Square test with a significance of p<0.05.
Results - 4,551 men were included for analysis with a mean age of 45.5 years (Range: 15-96, Std.Dev: 13.197). 49% (n=2242) of men were on TST and 51% (n=2.309) were not.
There was a greater prevalence of hypoprolactinemia in men on TST than in men not on TST for prolactin cut-points of <6 ng/mL (40.4% vs. 29.6%, p=0.001) and <3 ng/mL (3.4% vs. 1.8%, p=0.001). There was no statistical difference in the prevalence of profound hypoprolactinemia (<1ng/mL) between men on TST and not on TST (0.4% vs. 0.1%, p=0.074).
Conclusions - Prolactin appears to be involved in the central control of sexual function through modulation of dopaminergic and serotoninergic systems.
Hypoprolactinemia has also been associated with metabolic syndrome, arteriogenic erectile dysfunction, premature ejaculation, and anxiety.
Our study demonstrated that there is a greater prevalence of hypoprolactinemia in men taking testosterone supplementation therapy when compared to men not taking exogenous testosterone.
Given this finding, patients on TST may need to be monitored for possible development of signs and symptoms related to low prolactin levels.